THE ATP-BINDING CASSETTE (ABC) proteins comprise a large superfamily of transmembrane proteins that use the energy of ATP hydrolysis to translocate their substrates across biological membranes (23) . One branch of the superfamily, known as subfamily C, presently consists of 12 human proteins, 7 of which are designated as multidrug resistance proteins (MRPs) 1-7 (4, 9, 29) . MRP1 (ABCC1) was the first of the MRP-related transporters to be cloned (7) , and increased expression of this protein in tumor cells results in resistance to a remarkably diverse spectrum of anticancer drugs. MRP1 is also a primary active transporter of a variety of organic anions that include both endo-and xenobiotic molecules conjugated to GSH, glucuronide, and sulfate (9) .
The ability of MRP1 to confer resistance in tumor cells and to transport conjugated organic anions is shared by the structurally related MRP2 (ABCC2) and MRP3 (ABCC3). All three proteins have an extracytosolic NH 2 terminus and are predicted to have 17 transmembrane (TM) helices, which are organized as three membrane-spanning domains (MSD) (4, 28) (Fig. 1A) . The first, MSD1, contains five TM segments, whereas MSD2 and MSD3 are each predicted to contain six TM segments in most topological models (12, 21, 24) . MSD2 and MSD3 are each followed by a nucleotide-binding domain (NBD1 and NBD2), both of which are required for transport activity (9) .
The partial cDNA sequence of human MRP3 (ABCC3) and its mapping to chromosome 17p21, as well as the tissue distribution of human MRP3 mRNA, were first described by Kool et al. (26) . Shortly thereafter, the complete coding sequences of human MRP3 and rat Mrp3 were reported by several groups (3, 11, 22, 25, 27, 41) . The 1527-amino acid MRP3 protein exhibits 58% identity with MRP1 and 48% identity with MRP2. Despite this primary sequence similarity, MRP3, like MRP1 and MRP2, has its own distinctive pattern of tissue distribution and substrate specificity.
The highest levels of MRP3 mRNA are found in the liver, colon, and small intestine, whereas lower levels have been detected in pancreas, kidney, prostate, placenta, adrenal gland, and different parts of the brain (3, 11, 22, 39) . Immunohistochemical studies have for the most part corroborated the mRNA expression studies, and in all polarized epithelial cells examined to date MRP3, like MRP1, has been localized to basolateral membranes (22, 25, 27, 38) . In hepatocytes and intrahepatic bile duct epithelial cells (cholangiocytes), expression of MRP3 is induced during cholestasis, when apical expression of Mrp2/MRP2 is disrupted, such as in TR Ϫ rats and in humans with Dubin-Johnson syndrome. Under these conditions, MRP3 is thought to play a compensatory role in the basolateral efflux of toxic organic anions (32) . Hepatic MRP3/Mrp3 can also be induced in response to a number of different xenobiotics (5, 22, 34) .
Tumor cells transfected with MRP3 cDNA have been reported to be resistant to a relatively narrow spectrum of anticancer drugs. Thus MRP3 confers resistance to the podophyllotoxins VP-16 (etoposide) and VM-26 (teniposide), the antifolate methotrexate (MTX), and possibly the Vinca alkaloid vincristine but not to anthracyclines, platinum-containing drugs, or heavy metal oxyanions that are substrates of MRP1 or MRP2 (27, 43, 44) . Glutathione-and glucuronide-conjugated organic anions such as the cysteinyl leukotriene, leukotriene C 4 (LTC 4 ), and the conjugated estrogen, 17␤-estradiol 17␤(D-glucuronide) (E 2 17␤G), are also substrates of MRP3, as they are for MRP1 and MRP2. However, glucuronide conjugates appear to be transported by MRP3 with substantially greater efficiency than glutathione conjugates (14, 43, 46) . Finally, in addition to cytotoxic drugs and conjugated organic anions, MRP3 transports primary bile acids, such as cholic acid, taurocholic acid, and glycocholic acid, as well as conjugated secondary bile acids such as taurolithocholate-3-sulfate and cholate 3-O-glucuronide (14, 46) . In contrast, MRP1 and MRP2 transport only conjugated bile acids (15, 24, 32, 40) . Thus the substrate specificity of MRP3 overlaps but is distinct from that of either MRP1 or MRP2.
Amino acid residues in MRP3 involved in the recognition and transport of its substrates remain largely unknown. In previous studies of the related MRP1 and MRP2, we demonstrated that a highly conserved Trp residue in the highly amphipathic TM17 of MSD3 plays a critical role in the substrate specificity of these transporters (17, 18) (Fig. 1B) . In the present study, we have substituted the analogous residue in MRP3, Trp 1242 , with both conserved and nonconserved amino acids and examined the effects on the expression and substrate specificity of this bile salt transporter. Vector construction and site-directed mutagenesis. To generate an MRP3 expression vector, several DNA fragments containing the complete coding sequence of human MRP3 mRNA with an optimized Kozak sequence were synthesized by PCR and assembled in the vector pBluescript II KS ϩ (Stratagene, La Jolla, CA) as described elsewhere (C. J. Westlake, M. Vasa, S. P. C. Cole, and R. G. Deeley, unpublished observations). The coding sequence of MRP3 cDNA was then moved into the pcDNA3.1(ϩ) expression vector (Invitrogen, Burlington, ON, Canada), and the integrity of the resulting pcDNA3.1(ϩ) MRP3 construct was confirmed by sequencing the entire inserted sequence in both directions. The sequence obtained was in agreement with that published previously (GenBank accession no. CAA76658 gi: 3087794) (25) .
MATERIALS AND METHODS

Materials
Mutagenesis was carried out in the pBluescript II KS ϩ MRP3 plasmid using the Quik Change site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions. Oligonucleotides used for site-directed mutagenesis were synthesized by ACGT (Toronto, ON, Canada). Silent mutations introducing a DraI restriction site were incorporated into the mutagenic primers to aid in screening. Mutations for Trp 1242 substitutions (underlined), silent DraI restriction sites (italicized), and their corresponding oligonucleotides were as follows: W1242A (5Ј-G CAG GTG ACA TTC GCT TTA AAC GCG ATG ATA CGA ATG ATG TCA G-3Ј), W1242C (5Ј-G CAG GTG ACA TTC GCT TTA AAC TGC ATG ATA CGA ATG ATG TCA G-3Ј), W1242F (5Ј-G CAG GTG ACA TTC GCT TTA AAC TTC ATG ATA CGA ATG ATG TCA G-3Ј), W1242Y (5Ј-G CAG GTG ACA TTC GCT TTA AAC TAC ATG ATA CGA ATG ATG TCA G-3Ј), and W1242P (5Ј-G CAG GTG ACA TTC GCT TTA AAC CCG ATG ATA CGA ATG ATG TCA G-3Ј). After the presence of all mutations was confirmed by a DraI diagnostic digestion, a 0.3-kb AgeI/PmaCI fragment containing the desired mutation was subcloned back into pcDNA3.1(ϩ)MRP3 and the entire fragment in the full-length construct was sequenced.
Transient transfections of MRP3 expression vectors. Mutant pcDNA3.1(ϩ)MRP3 expression vectors were transfected into SV40-transformed human embryonic kidney cells (HEK293T) as before (17) . Briefly, ϳ5 ϫ 10 6 cells were seeded in 150-mm dishes, and 24 h later DNA (16 g) was added using FuGENE 6 (Roche Diagnostics, Laval, PQ, Canada) according to the manufacturer's instructions. After 48-72 h, the HEK293T cells were harvested and inside-out membrane vesicles were prepared as described previously (30) . Empty vector pcDNA3.1(ϩ) DNA and vector containing the wildtype MRP3 cDNA were included as controls in all transfection experiments.
Measurement of MRP3 protein levels in transfected cells. The relative levels of wild-type and Trp 1242 mutant MRP3 proteins were determined by immunoblot analysis of membrane protein fractions from the transfected cells essentially as described (17) . Proteins were resolved on a 6% polyacrylamide gel and electrotransferred to a nylon membrane. Membranes were blocked with 4% (wt/vol) skim milk powder in Tris-buffered saline with 0.1% Tween 20 (vol/vol) (TBST) for 1 h followed by incubation with the MRP3-specific murine MAb M 3II-9 (Alexis, San Diego, CA) diluted 1:1,000 to 1:10,000 in 4% skim milk powder in TBST. After being washed, blots were incubated with horseradish peroxidaseconjugated goat anti-mouse antibody diluted 1:10,000 (Pierce, Edmonton, AB, Canada) followed by application of Renaissance chemiluminescence blotting substrate (NEN Life Science). Relative levels of MRP3 protein expression were estimated by densitometric analysis using a ChemiImager 4000 (Alpha Innotech, San Leandro, CA).
MRP3-mediated transport of [ 3 H]E217␤G and [
3 H]LTC4 by inside-out membrane vesicles. ATP-dependent transport of 3 H-labeled substrates by the membrane vesicles was measured by using a rapid filtration technique as described previously (18, 30) . Briefly, time courses of E217␤G uptake were performed at 37°C in a 60-l reaction volume containing 400 nM [ 3 H]E217␤G (120 nCi), 4 mM AMP or ATP, 10 mM MgCl 2, 10 mM creatine phosphate, 100 g/ml creatine kinase, and 6 g of vesicle protein in transport buffer (50 mM Tris ⅐ HCl, 250 mM sucrose, pH 7.4). In some experiments, MTX, taurocholate, and glycocholate were added at the concentrations indicated. Uptake was stopped at the appropriate times by rapid dilution of an aliquot of the reaction mixture in ice-cold transport buffer and then filtered through glass fiber (type A/E) filters that had been presoaked in transport buffer. Radioactivity was quantitated by liquid scintillation counting. All data were corrected for the amount of [ 3 H]E217␤G that remained bound to the filter, which was usually Ͻ10% of the total radioactivity. Uptake in the presence of AMP was subtracted from uptake in the presence of ATP to determine ATP-dependent at the predicted COOH-proximal cytosol-membrane interface of TM17 can dramatically affect the substrate specificity of MRP1 and MRP2, respectively, cDNA constructs were generated in which the analogous residue, Trp 1242 , in MRP3 was replaced with several different amino acids. These included nonconservative substitutions with a nonaromatic nonpolar amino acid (Ala; W1242A-MRP3) and a nonaromatic polar amino acid (Cys; W1242C-MRP3), as well as conservative substitutions with aromatic polar (Tyr; W1242Y-MRP3) and nonpolar (Phe; W1242F-MRP3) amino acids. Trp 1242 was also replaced with a ␣-helix-disrupting residue (Pro; W1242P-MRP3). The cDNA constructs were transfected into HEK293T cells, and after 48-72 h the cells were harvested, the membrane vesicles were prepared, and relative MRP3 protein levels were determined by immunoblotting. As shown in Fig. 2 , wildtype MRP3 and the four mutants (W1242A-, W1242C-, W1242F-, and W1242Y-MRP3) were expressed at similar levels. In contrast, the W1242P-MRP3 mutant was expressed at significantly lower levels, suggesting that this mutation affects the biogenesis or stability of the protein. Mean expression levels of the mutant MRP3 proteins relative to wild-type MRP3 were as follows: W1242A, 1.1 Ϯ 0.3; W1242C, 1.0 Ϯ 0.2; W1242Y, 1.0 Ϯ 0.1; W1242F, 1.0 Ϯ 0.3; and W1242P, 0.6 Ϯ 0.2 (4-6 independent transfections).
Substitution of Trp 1242 enhances the ability of MRP3 to transport [ 3 H]E 2 17␤G. Time courses of ATP-dependent [
3 H]E 2 17␤G uptake were determined for the W1242A-, W1242C-, W1242F-, W1242Y-, and W1242P-MRP3 mutants by using inside-out membrane vesicles prepared from transfected HEK293T cells (Fig. 3A) . Unexpectedly, four of the five mutants (W1242A-, W1242C-, W1242F-, and W1242Y-MRP3) transported this glucuronide substrate at levels that were substantially higher than those of wild-type MRP3. In contrast, transport by W1242P-MRP3 was almost undetectable. At 3 min, [ 3 H]E 2 17␤G uptake in membrane vesicles enriched for W1242A-, W1242C-, and W1242F-MRP3 was 2.5-to 3-fold higher than for wild-type MRP3, whereas [ 3 H]E 2 17␤G uptake by the most conservatively substituted mutant, W1242Y-MRP3, was ϳ7-fold higher (Fig. 3B) .
Effect 4 . Previous studies of rat and human Mrp3/MRP3 have reported that glutathione conjugates such as LTC 4 are relatively poor substrates for this ABC transporter (13, 43, 46) . We also observed that [ 3 H]LTC 4 uptake by wild-type MRP3 was very low when measured at an initial substrate concentration of 50 nM [6.3 Ϯ 0.5 pmol/mg protein for WT-MRP3 vs. 5.4 Ϯ 0.6 pmol/mg protein for pcDNA3.1(ϩ) vector control; not shown]. This concentration is commonly used in LTC 4 uptake assays by MRP1 and MRP2 and is severalfold higher than the concentration used in some previous studies of MRP3/Mrp3 (13, 46) . However, we found that when transport assays were carried out at a 10-fold higher initial LTC 4 concentration (500 nM), in keeping with the lower affinity of this transporter for this glutathione conjugate, significant levels of uptake were observed. Thus ATP-dependent [ 3 H]LTC 4 uptake by membrane vesicles from cells transfected with wildtype MRP3 cDNA was 94 Ϯ 1 vs. 25 Ϯ 2 pmol/mg protein for membrane vesicles from cells transfected with the pcDNA3.1(ϩ) vector alone (Fig. 4A) 4 uptake by the W1242A-, W1242F-, and W1242Y-MRP3 mutants was somewhat less than the wild-type MRP3 transport activity (Fig. 4A) . At 5 min, levels of [ 3 H]LTC 4 uptake by these three mutants were ϳ62-70% those of wild-type MRP3, whereas uptake by the W1242C-MRP3 mutant was only 37% of wild-type levels (after subtraction of uptake by vector control membrane vesicles and normalization of mutant MRP3 protein levels to wild-type MRP3 protein levels) (Fig. 4B) (Fig. 5A ). This rate is more than twofold higher than those reported previously for human MRP3 expressed in stably transfected HEK293T cells, which may simply reflect higher levels of MRP3 expression in our HEK transfectants (45 mutants were ϳ12-26% those of wild-type MRP3 [after the transport activity of the pcDNA3.1(ϩ) vector control was subtracted and values normalized for relative MRP3 protein expression] (Fig. 5B) . A similar reduction in MTX transport activity was observed when assays were carried out at a 100-fold higher initial substrate concentration (100 (Fig. 7A) . Taurocholate uptake by the W1242A-, W1242C-, W1242F-, and W1242Y-MRP3 mutants was then examined and, in all cases, was not significantly different from uptake by wild-type MRP3 (Fig. 7B) . Consistent with this observation, [ 3 H]E 2 17␤G uptake by W1242A-, W1242C-, W1242F-, and W1242Y-MRP3 could still be inhibited by taurocholic acid (40-60%) at concentrations of 50 and 100 M (Fig. 7C) . Glycocholic acid also inhibited [ 3 H]E 2 17␤G uptake by the four MRP3-Trp 1242 mutant proteins, and this inhibition was similar to that observed with wild-type MRP3. At concentrations of 50 and 100 M, inhibition by glycocholic acid ranged from 40 to 80% (Fig. 8) .
The transport activities of the MRP3-Trp 1242 mutants for the five substrates tested are summarized in (17) , and MRP3-Trp 1242 on transport activity are summarized in Table 2 .
DISCUSSION
In addition to its potential role as a cause of drug resistance in tumor cells in which it is overexpressed, MRP3 is a primary active transporter of both primary Fig. 7 and secondary bile salts (13, 20, 46) . The majority of bile salt transport in the liver takes place across the apical canalicular membrane and is mediated by bile salt export protein (BSEP; ABCB11) (32) . However, because of the relatively high level of MRP3 expression in the liver, its inducibility in this tissue, and its location on basolateral membranes, it has been postulated that MRP3 may contribute to the enterohepatic circulation of bile salts that is essential for the maintenance of bile acid and cholesterol homeostasis (16, 32, 34) . In this respect, the substrate specificity of MRP3 differs from the related MRP1 and MRP2, which confer resistance to a much broader range of anticancer drugs than MRP3 but are limited to transporting only conjugated bile salts. Thus all three of these ABCC proteins transport conjugated organic anions, but there are marked differences in the affinity and efficiency with which they do so (2, 24, 29, 40, 46) .
Factors governing the substrate specificity of the MRP-related transporters are complex, as can be expected for any relatively large polytopic membrane protein that recognizes such a variety of different substrates. To date, a number of conserved and nonconserved amino acids in different regions of MRP1 have been shown to affect the substrate specificity and transport efficiency of this protein (8, 9, 18, 47, 48) . Similarly, sequence analyses of MRP2/Mrp2 in humans with Dubin-Johnson syndrome and in hyperbilirubinemic TR Ϫ /EHBR rats, respectively, as well as site-directed mutagenesis studies have identified amino acids important for the function of this transporter (17, 19, 20, 33, 37, 42) . In contrast, comparatively little is known about the amino acids that determine the substrate specificity of MRP3. However, by taking advantage of amino acid sequence differences between rat Mrp3 and Mrp2, Ito et al. (20) recently identified a nonconserved Leu residue at position 1084 in predicted TM14 of rat Mrp3 as being important for the ability of this protein to transport taurocholic acid. Thus substitution of Leu 1084 in Mrp3 with Lys (as it is in MRP1) eliminated both taurocholic acid and E 2 17␤G uptake, suggesting that these two substrates share at least one common binding determinant in a substratebinding pocket of this transporter. In the present study, we have shown that mutation of the highly conserved Trp 1242 in TM17 of human MRP3, like the nonconserved Leu 1084 in rat Mrp3, significantly alters the ability of this protein to transport E 2 17␤G, but in the case of MRP3-Trp 1242 , transport activity was markedly increased rather than decreased. Also in contrast to the rat Mrp3-Leu 1084 mutant, the MRP3-Trp 1242 mutants retained their ability to transport taurocholic acid and E 2 17␤G transport by these mutants could still be inhibited by bile acid. Thus it appears that E 2 17␤G and taurocholic acid share an overlapping but not identical set of binding determinants in a substratebinding pocket of MRP3/Mrp3. Our observation that all substitutions of MRP3-Trp 1242 markedly stimulated E 2 17␤G uptake was unexpected, because both conservative and nonconservative substitutions of the analogous Trp 1246 in MRP1 had the opposite effect and essentially eliminated transport of this conjugated estrogen, as did nonconservative substitutions of MRP2-Trp 1254 (17, 18) (Table  2) . Trp residues with their large indole (benzopyrrole) side chains have the greatest steric bulk of all of the amino acids (36) . Thus all Trp substitutions examined in the present study resulted in mutant MRP3 proteins MRP, multidrug resistance protein; E217␤G, 17␤-estridiol 17␤(Dglucuronide); LTC4 leukotriene C4; MTX, methotrexate; 7, no effect; 1, increased 2.5-to 3-fold compared with wild-type MRP3 activity; 11, increased 7-fold; 2, decreased 25-50% compared with wildtype MRP3 activity; 22, decreased 50-75%; 222, decreased Ն 75%; n.d., not determined.
with less steric bulk at position 1242 than is found in the wild-type protein. This could allow for greater freedom of motion in the E 2 17␤G-binding pocket of MRP3 or possibly enhance the flexibility of TM17, which might increase the transport efficiency of this substrate. However, the highest level of E 2 17␤G uptake was observed with W1242Y-MRP3, which is the most conservatively substituted mutant with respect to steric bulk, aromaticity, and H-bonding capability of the lateral side chain. Thus only a relatively small reduction in steric bulk seems required to enhance E 2 17␤G transport efficiency by MRP3.
In contrast to E 2 17␤G uptake, the variously substituted MRP3-Trp 1242 mutants all showed reduced LTC 4 transport, but the decrease was moderate (25-50%). We showed previously that the MRP1-Trp 1246 was critical for E 2 17␤G transport as well as being essential for conferring drug resistance (18) . However, LTC 4 transport by the MRP1-Trp 1246 mutants was similar to wildtype MRP1 with just a small decrease in K m . This contrasts with the findings with MRP2-Trp 1254 mutants, where nonconservative substitutions completely eliminated the ability of MRP2 to transport this cysteinyl leukotriene (17) ( Table 2) .
MRP1 and MRP2 are low-affinity transporters of GSH, and, at least in the case of MRP1, GSH transport can be markedly enhanced by a variety of compounds, including vincristine, phenylalkylamines such as verapamil, and bioflavonoids such as apigenin (2, 28, 29, 31, 35) . In contrast, despite the higher degree of amino acid similarity between MRP1 and MRP3 than between MRP1 and MRP2, there is no evidence that MRP3 transports GSH alone (27, 43) nor can it be stimulated by verapamil or bioflavonoids (C. J. Oleschuk, I. Letourneau, R. G. Deeley, and S. P. C. Cole, unpublished observations). Efflux of drugs such as the Vinca alkaloids vincristine and vinblastine and the anthracyclines doxorubicin and daunorubicin by MRP1 and MRP2 seems to occur in a cotransport manner with GSH. Whether the inability of MRP3 to confer resistance to these two classes of drugs is related to its inability to transport GSH is not yet known. Also uncertain is whether the apparent inability of MRP3 to transport GSH is related to the relatively poor affinity of this transporter for GSH conjugates compared with glucuronide conjugates. However, it is clear that factors other than binding of a GSH moiety contribute to GS-X and GSH transport, because LTC 4 transport by MRP3 is readily detectable.
Introduction of a Pro residue at position 1242 was the only substitution that completely eliminated the conjugated organic anion transport activity of MRP3. This substitution would not only change the spatial volume occupied by the side chain and disrupt the potential H-bonding and aromatic stacking interactions of the amino acid at this position, but it would also introduce a kink into TM17 at the predicted membrane-cytosol interface (36) . The loss of H-bonding and aromatic stacking interactions alone cannot fully account for the inactivity of the W1242P-MRP3 mutant, because the Ala, Cys, Phe, and Tyr mutants all retained some transport activity. Rather, it is more likely that the unique helix-modifying properties of Pro caused a more global disruption of the substrate-binding pocket of MRP3 that was sufficient to abrogate the overall transport activity of the protein. In this regard, it is also of interest that none of the substitutions of MRP3-Trp 1242 significantly affected protein expression levels, with the exception of the Pro substitution. Again, it may be that the helix-modifying properties of this amino acid adversely affected the proper packing of the TM segments of MRP3 so as to reduce the stability of the protein, which could also contribute to the elimination of transport.
Previously, we reported that MTX transport was essentially eliminated by all MRP2-Trp 1254 substitutions (17) , and the same is true of the MRP1-Trp 1246 mutants (I. Letourneau, C. J. Oleschuk, K. Ito, R. G. Deeley, and S. P. C. Cole, unpublished observations; see Table 2 ). However, the MRP3-Trp 1242 mutants retained a low level of MTX transport activity, which is consistent with the observation that MTX was still able to partially inhibit E 2 17␤G uptake by the MRP3-Trp 1242 mutants. These findings suggest that the conserved Trp residue may be more important for maintaining the architecture of the MTX substrate-binding pocket of MRP1 and MRP2 than MRP3. We also found that, with the exception of the Tyr substitution, all MRP3-Trp 1242 mutations caused a marked decrease in the ability of MRP3 to transport leucovorin. This agent is used clinically as a rescue agent to reduce bone marrow toxicity associated with antifolate treatment (6) , and it has been previously reported that the affinity of MRP3 is about threefold lower for leucovorin than it is for MTX (45) . The basis for this difference in affinity is unknown but is likely to be related to differences in the interactions of these drugs with a folatebinding pocket in MRP3. These drugs, like the Trp residue itself, are capable of both H-bonding and aromatic stacking interactions. It is not presently possible to know whether or not such direct interactions occur between MRP3-Trp 1242 and these drugs. However, if they do, they must do so in a somewhat different way for leucovorin than for MTX, which may account for the difference in affinities of these compounds for MRP3 as well as for the ability of the W1242Y-MRP3 mutant to transport the former but not the latter drug. As a polar aromatic amino acid, Tyr is considered a conservative substitution of Trp. Nevertheless, the two amino acids differ in certain significant ways that could affect interactions with different MRP3 substrates. These differences include the spatial volumes occupied by the side chains of Trp and Tyr (174 Å 3 and 143 Å 3 , respectively) as well as the potential H-bonding interactions of the indole ring of the Trp side chain vs. the hydroxyl group of the Tyr side chain.
In summary, our studies show that the highly conserved Trp residue in MRP3 at the membrane-cytosol interface of TM17, as shown previously for MRP1 and MRP2, plays a unique and selective role in substrate recognition by this protein. Importantly, they show that, although the transport of a variety of organic anion substrates are affected by changes in this amino acid, binding and transport of bile salts appear to remain intact. Furthermore, our findings, together with those of Ito et al. (20) , who identified a critical Leu residue in TM14 of rat Mrp3, suggest that, as we have shown previously for MRP1 (47) , interactions between TM14 and TM17 may be required for MRP3/Mrp3 to transport at least some of its substrates. Finally, they also reaffirm the important notion that prediction of the substrate specificity of an ABC transporter solely on the basis of its amino acid conservation, either with homologs in the same species or orthologs in different species, is not possible.
